4.24
price up icon1.92%   0.08
after-market Handel nachbörslich: 4.24
loading

Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten

pulisher
03:22 AM

JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World

03:22 AM
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans - Investing.com

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire Inc.

May 01, 2025
pulisher
Apr 29, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents Preclinical Data at AACR 2025 - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan

Apr 28, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World

Apr 26, 2025
pulisher
Apr 23, 2025

This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 23, 2025
pulisher
Apr 23, 2025

JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 18, 2025

Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World

Apr 18, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Major Pipeline Breakthrough: Foghorn's First-in-Class Cancer Drug Shows Promise in NSCLC Treatment - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Wellington Management Group LLP - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Trading 4.1% Higher – Time to Buy? - Defense World

Apr 15, 2025
pulisher
Apr 09, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely - simplywall.st

Apr 09, 2025
pulisher
Apr 07, 2025

(FHTX) Technical Data - news.stocktradersdaily.com

Apr 07, 2025
pulisher
Apr 02, 2025

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - MSN

Apr 02, 2025
pulisher
Mar 27, 2025

Trend Tracker for (FHTX) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients (NASDAQ:FHTX) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - The AM Reporter

Mar 26, 2025
pulisher
Mar 25, 2025

Foghorn Therapeutics Announces New Preclinical Data for - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World

Mar 24, 2025
pulisher
Mar 22, 2025

2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc. - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Foghorn Therapeutics adjusts ATM offering to $100M By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Foghorn Therapeutics adjusts ATM offering to $100M - Investing.com

Mar 20, 2025
pulisher
Mar 18, 2025

Research Analysts Offer Predictions for FHTX Q1 Earnings - The AM Reporter

Mar 18, 2025
pulisher
Mar 18, 2025

What is B. Riley’s Forecast for FHTX Q1 Earnings? - Defense World

Mar 18, 2025
pulisher
Mar 13, 2025

Foghorn Therapeutics Reports Progress and Financial Stability - TipRanks

Mar 13, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Purchases 3,049 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Foghorn Therapeutics’ (FHTX) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Foghorn Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Can Foghorn's $243M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan

Mar 06, 2025
pulisher
Mar 01, 2025

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN

Mar 01, 2025
pulisher
Feb 28, 2025

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo

Feb 28, 2025
pulisher
Feb 27, 2025

Foghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 25, 2025

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire

Feb 25, 2025
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Kapitalisierung:     |  Volumen (24h):